ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000875

Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease

Identifieur interne : 000875 ( PascalFrancis/Corpus ); précédent : 000874; suivant : 000876

Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease

Auteurs : Katie Wiltshire ; Sheri Foster ; Jeffrey A. Kaye ; Brent J. Small ; Richard Camicioli

Source :

Dementia and geriatric cognitive disorders [ 1420-8008 ] ; 2005.

RBID : Pascal:06-0002537

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Démence, Trouble cognition, Parkinson maladie, Maladie dégénérative, Corps calleux, Imagerie RMN.

English descriptors

KwdEn :
- Cognitive disorder, Corpus callosum, Degenerative disease, Dementia, Nervous system diseases, Nuclear magnetic resonance imaging, Parkinson disease.

Abstract

Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T₁-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% Cl, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p> 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1420-8008`
A03		`1`		`@0 Dement. geriatr. cogn. disord.`
A05				`@2 20`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease`
A11	`01`	`1`		`@1 WILTSHIRE (Katie)`
A11	`02`	`1`		`@1 FOSTER (Sheri)`
A11	`03`	`1`		`@1 KAYE (Jeffrey A.)`
A11	`04`	`1`		`@1 SMALL (Brent J.)`
A11	`05`	`1`		`@1 CAMICIOLI (Richard)`
A14	`01`			`@1 University of Alberta @2 Edmonton @3 CAN @Z 1 aut. @Z 2 aut. @Z 5 aut.`
A14	`02`			`@1 Oregon Health and Science University @2 Portland, Oreg @3 USA @Z 3 aut.`
A14	`03`			`@1 University of South Florida @2 Tampa, Fla @3 USA @Z 4 aut.`
A20				`@1 345-351`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22106 @5 354000135170660030`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 48 ref.`
A47	`01`	`1`		`@0 06-0002537`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Dementia and geriatric cognitive disorders`
A66	`01`			`@0 CHE`
C01	`01`		`ENG`	@0 Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T₁-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% Cl, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p> 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B22D02`
C02	`03`	`X`		`@0 002B24A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Démence @5 02`
C03	`02`	`X`	`ENG`	`@0 Dementia @5 02`
C03	`02`	`X`	`SPA`	`@0 Demencia @5 02`
C03	`03`	`X`	`FRE`	`@0 Trouble cognition @5 03`
C03	`03`	`X`	`ENG`	`@0 Cognitive disorder @5 03`
C03	`03`	`X`	`SPA`	`@0 Trastorno cognitivo @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @5 04`
C03	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 05`
C03	`05`	`X`	`ENG`	`@0 Degenerative disease @5 05`
C03	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 05`
C03	`06`	`X`	`FRE`	`@0 Corps calleux @5 09`
C03	`06`	`X`	`ENG`	`@0 Corpus callosum @5 09`
C03	`06`	`X`	`SPA`	`@0 Cuerpo calloso @5 09`
C03	`07`	`X`	`FRE`	`@0 Imagerie RMN @5 10`
C03	`07`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 10`
C03	`07`	`X`	`SPA`	`@0 Imaginería RMN @5 10`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
N21				`@1 002`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0002537 INIST
ET :	Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease
AU :	WILTSHIRE (Katie); FOSTER (Sheri); KAYE (Jeffrey A.); SMALL (Brent J.); CAMICIOLI (Richard)
AF :	University of Alberta/Edmonton/Canada (1 aut., 2 aut., 5 aut.); Oregon Health and Science University/Portland, Oreg/Etats-Unis (3 aut.); University of South Florida/Tampa, Fla/Etats-Unis (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Dementia and geriatric cognitive disorders; ISSN 1420-8008; Suisse; Da. 2005; Vol. 20; No. 6; Pp. 345-351; Bibl. 48 ref.
LA :	Anglais
EA :	Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T₁-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% Cl, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p> 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.
CC :	002B17G; 002B22D02; 002B24A03
FD :	Système nerveux pathologie; Démence; Trouble cognition; Parkinson maladie; Maladie dégénérative; Corps calleux; Imagerie RMN
FG :	Encéphale pathologie; Extrapyramidal syndrome; Système nerveux central pathologie
ED :	Nervous system diseases; Dementia; Cognitive disorder; Parkinson disease; Degenerative disease; Corpus callosum; Nuclear magnetic resonance imaging
EG :	Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease
SD :	Sistema nervioso patología; Demencia; Trastorno cognitivo; Parkinson enfermedad; Enfermedad degenerativa; Cuerpo calloso; Imaginería RMN
LO :	INIST-22106.354000135170660030
ID :	06-0002537

Links to Exploration step

Pascal:06-0002537

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease</title>
<author><name sortKey="Wiltshire, Katie" sort="Wiltshire, Katie" uniqKey="Wiltshire K" first="Katie" last="Wiltshire">Katie Wiltshire</name>
<affiliation><inist:fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Foster, Sheri" sort="Foster, Sheri" uniqKey="Foster S" first="Sheri" last="Foster">Sheri Foster</name>
<affiliation><inist:fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaye, Jeffrey A" sort="Kaye, Jeffrey A" uniqKey="Kaye J" first="Jeffrey A." last="Kaye">Jeffrey A. Kaye</name>
<affiliation><inist:fA14 i1="02"><s1>Oregon Health and Science University</s1>
<s2>Portland, Oreg</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Small, Brent J" sort="Small, Brent J" uniqKey="Small B" first="Brent J." last="Small">Brent J. Small</name>
<affiliation><inist:fA14 i1="03"><s1>University of South Florida</s1>
<s2>Tampa, Fla</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation><inist:fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0002537</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0002537 INIST</idno>
<idno type="RBID">Pascal:06-0002537</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000875</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease</title>
<author><name sortKey="Wiltshire, Katie" sort="Wiltshire, Katie" uniqKey="Wiltshire K" first="Katie" last="Wiltshire">Katie Wiltshire</name>
<affiliation><inist:fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Foster, Sheri" sort="Foster, Sheri" uniqKey="Foster S" first="Sheri" last="Foster">Sheri Foster</name>
<affiliation><inist:fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kaye, Jeffrey A" sort="Kaye, Jeffrey A" uniqKey="Kaye J" first="Jeffrey A." last="Kaye">Jeffrey A. Kaye</name>
<affiliation><inist:fA14 i1="02"><s1>Oregon Health and Science University</s1>
<s2>Portland, Oreg</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Small, Brent J" sort="Small, Brent J" uniqKey="Small B" first="Brent J." last="Small">Brent J. Small</name>
<affiliation><inist:fA14 i1="03"><s1>University of South Florida</s1>
<s2>Tampa, Fla</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation><inist:fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Dementia and geriatric cognitive disorders</title>
<title level="j" type="abbreviated">Dement. geriatr. cogn. disord.</title>
<idno type="ISSN">1420-8008</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Dementia and geriatric cognitive disorders</title>
<title level="j" type="abbreviated">Dement. geriatr. cogn. disord.</title>
<idno type="ISSN">1420-8008</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cognitive disorder</term>
<term>Corpus callosum</term>
<term>Degenerative disease</term>
<term>Dementia</term>
<term>Nervous system diseases</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Démence</term>
<term>Trouble cognition</term>
<term>Parkinson maladie</term>
<term>Maladie dégénérative</term>
<term>Corps calleux</term>
<term>Imagerie RMN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T<sub>1</sub>
-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% Cl, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p> 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1420-8008</s0>
</fA01>
<fA03 i2="1"><s0>Dement. geriatr. cogn. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WILTSHIRE (Katie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FOSTER (Sheri)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KAYE (Jeffrey A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SMALL (Brent J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CAMICIOLI (Richard)</s1>
</fA11>
<fA14 i1="01"><s1>University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Oregon Health and Science University</s1>
<s2>Portland, Oreg</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of South Florida</s1>
<s2>Tampa, Fla</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>345-351</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22106</s2>
<s5>354000135170660030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>48 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0002537</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Dementia and geriatric cognitive disorders</s0>
</fA64>
<fA66 i1="01"><s0>CHE</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T<sub>1</sub>
-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% Cl, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p> 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B22D02</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B24A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Démence</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dementia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Demencia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble cognition</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Corps calleux</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Corpus callosum</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Cuerpo calloso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fN21><s1>002</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0002537 INIST</NO>
<ET>Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease</ET>
<AU>WILTSHIRE (Katie); FOSTER (Sheri); KAYE (Jeffrey A.); SMALL (Brent J.); CAMICIOLI (Richard)</AU>
<AF>University of Alberta/Edmonton/Canada (1 aut., 2 aut., 5 aut.); Oregon Health and Science University/Portland, Oreg/Etats-Unis (3 aut.); University of South Florida/Tampa, Fla/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Dementia and geriatric cognitive disorders; ISSN 1420-8008; Suisse; Da. 2005; Vol. 20; No. 6; Pp. 345-351; Bibl. 48 ref.</SO>
<LA>Anglais</LA>
<EA>Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T<sub>1</sub>
-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% Cl, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p> 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to - 0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.</EA>
<CC>002B17G; 002B22D02; 002B24A03</CC>
<FD>Système nerveux pathologie; Démence; Trouble cognition; Parkinson maladie; Maladie dégénérative; Corps calleux; Imagerie RMN</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Dementia; Cognitive disorder; Parkinson disease; Degenerative disease; Corpus callosum; Nuclear magnetic resonance imaging</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Demencia; Trastorno cognitivo; Parkinson enfermedad; Enfermedad degenerativa; Cuerpo calloso; Imaginería RMN</SD>
<LO>INIST-22106.354000135170660030</LO>
<ID>06-0002537</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000875 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000875 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0002537
   |texte=   Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease

Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri